The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer. (2017)
Attributed to:
Novel strategies to improve the effectiveness of radiation and targeted therapies in lung cancer
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1158/1078-0432.ccr-16-3216
PubMed Identifier: 28559461
Publication URI: http://europepmc.org/abstract/MED/28559461
Type: Journal Article/Review
Volume: 23
Parent Publication: Clinical cancer research : an official journal of the American Association for Cancer Research
Issue: 18
ISSN: 1078-0432